



Cite this: *Biomater. Sci.*, 2016, **4**, 25

Composite biopolymers for bone regeneration enhancement in bony defects

K. Jahan^a and M. Tabrizian^{*a,b}

Received 28th May 2015,
Accepted 11th August 2015

DOI: 10.1039/c5bm00163c

www.rsc.org/biomaterialsscience

For the past century, various biomaterials have been used in the treatment of bone defects and fractures. Their role as potential substitutes for human bone grafts increases as donors become scarce. Metals, ceramics and polymers are all materials that confer different advantages to bone scaffold development. For instance, biocompatibility is a highly desirable property for which naturally-derived polymers are renowned. While generally applied separately, the use of biomaterials, in particular natural polymers, is likely to change, as biomaterial research moves towards mixing different types of materials in order to maximize their individual strengths. This review focuses on osteoconductive biocomposite scaffolds which are constructed around natural polymers and their performance at the *in vitro/in vivo* stages and in clinical trials.

Introduction

Non-union or mal-union fractures resulting in bone defects remain a big challenge in the field of bone tissue engineering. A bone defect is defined as the smallest size defect that will not repair without medical intervention.¹ Depending on the bone involved, the “critical size” of a non-union defect may vary: forearm (3 cm), femur and tibia (5 cm) and humerus (6 cm).² Autologous bone grafts are currently the gold standard in bone repair, followed by allografts (from another individual

and xenografts (from an animal). However, donor shortages and donor site morbidity are amongst these treatments’ several shortcomings.³ This has led to ample research on alternative bone graft materials such as polymers, metals and ceramics. Their role is not only to fill the bone fissure but also to provide both structural and mechanical support. An increasing number of natural and synthetic graft materials are under development with composites being favoured as they combine all the advantageous properties of the individual monolithic biomaterials. An investigation of the literature has shown that even though synthetic polymers have been widely used in bone research over the past ten years, the same cannot be said about naturally-derived polymers (Fig. 1). While the use of synthetic polymers has increased substantially over time, the use of naturally-derived polymers has remained steady, despite

^aFaculty of Dentistry, McGill University, 3640 University Street, Montreal, QC H3A 2B2, Canada. E-mail: maryam.tabrizian@mcgill.ca

^bBiomedical Engineering, Duff Medical Building, Room 313, McGill, Montreal, H3A 2B4, Canada



K. Jahan

Kaushar Jahan completed her Bachelor's degree in Anatomy and Cellular Biology at McGill University. During her undergraduate studies she acquired extensive skills in molecular and cell biology. She then started her Master's degree exploring 2D scaffolds for bone regeneration with Dr Maryam Tabrizian and fast-tracked into the PhD program to further develop an injectable 3D scaffold for bone repair in critical-sized defect models.



M. Tabrizian

Maryam Tabrizian is full professor in the Biological and Biomedical Engineering Department at McGill University. She is a Guggenheim Fellow in Biomedical Sciences and a Fellow of the Biomaterials Science & Engineering. She has established expertise in designing advanced biomaterials and bioactive bio-interface for application in nanomedicine, regenerative medicine and Lab-on-a-chip devices.




Fig. 1 Graph displaying the total number of publications on polymers used in bone tissue engineering vs. naturally-derived polymers used in the same field. Source: Web of Science, 2015.

their abundance in nature and their biocompatibility. In this review, we aim to cover naturally-derived polymer-based bio-composites reported in the past 10 years and to present their potential as a material of choice for bone.

Biology of bone

Bone composition

Bone is a specialized connective tissue made of calcified matter called the bone matrix, and three dominant types of cells. Osteoblasts are the cells that synthesize and release the organic material of bone. Osteocytes, cells deriving from mature osteoblasts, are found within calcified bone in cavities called lacunae. Lastly, osteoclasts are large multinucleated cells with projections that play a key role in bone resorption to maintain bone homeostasis. The bone matrix is composed of both organic and inorganic material. The inorganic material includes calcium hydroxyapatite, bicarbonate, potassium and magnesium ions among others. The organic part is made of proteins such as type I collagen, as well as proteoglycans and glycoproteins. The organic components are embedded within the calcified matrix. Anatomically, bone tissue has two distinct structures: compact (80%) and cancellous (20%) bones. Compact bone is a denser structure found at the surface whereas cancellous bone is a cavity-filled structure found in the deeper areas of the bone. For a more extensive review of bone composition, please refer to Junqueira's Basic Histology.⁴

Bone formation

Bone development starts in the first few weeks of embryogenesis through two stages: osteogenesis which is the bone formation, and ossification which is the mineralization process.^{6,7} Two types of ossification take place *via* the condensation of mesenchymal stem cells (MSCs).⁸ The first is an


intra-membranous ossification for the development of flat bones, and the second is an endochondral ossification (Fig. 2) for other types of bone.⁵ During intra-membranous ossification the MSCs will differentiate into pre-osteoblasts and osteoblasts, which will in turn produce extracellular matrix proteins that become mineralized.⁹ These bone deposits, also known as spicules, fuse together to form a trabecular bone. This will form a periosteum on the outer surface. Mature trabeculae will replace the immature trabeculae during the secondary bone formation.¹⁰ The endochondral ossification forms through a structure called the cartilage template.

MSCs condense and differentiate into chondrocytes. The latter will deposit hyaline cartilage that will act as a template for bone formation. This cartilage will undergo interstitial growth to lengthen and appositional growth to widen. The matrix will begin to calcify and large chondrocytes amidst the matrix will die, leaving holes. This progression is regulated *via* several signaling pathways such as Hedgehog, bone morphogenic proteins (BMPs), transforming growth factor beta (TGF- β), Wnt and parathyroid hormone (PTH).⁷ Meanwhile blood vessels start growing closer to the cartilage, and osteoblast differentiation is induced within the outer layer of the hyaline cartilage, the perichondrium. The osteoblasts create a bone collar that grows to become compact bone. At this point, the perichondrium is referred to as the periosteum.^{11,12} The blood vessels now invade the cartilage in the central region and introduce mesenchymal and hematopoietic stem cells. Both these cells differentiate into osteoblasts which form the trabecular bone; this is the primary ossification center. The cartilage gets replaced by the bone along the shaft. This is followed by the formation of the marrow cavity *via* bone remodelling. The blood vessels bring in monocytes that will differentiate into osteoclasts, which are bone resorbing cells.⁹ The marrow cavity is enlarged by the resorption of the trabecular bone and is eventually replaced by red bone marrow. The diaphysis elongates while the cortical bone thickens. The bone also replaces the cartilage at the metaphysis. Next, the blood vessels invade the epiphyses at each end of the bone and introduce osteoblasts. Ossification ensues just like in the primary ossification center, except that no medullary cavity is formed this time. The cartilage at the epiphyses is mostly replaced by the trabecular bone except at two distinct locations: (i) articular cartilage covering the bone at the joint and (ii) the growth plate that separates the epiphysis from the diaphysis.^{13,14}

Bone regeneration

Fracture healing involves both types of ossification. Immediately following a fracture, there is a haematoma formation due to the torn blood vessels. A mass of clotted blood will rise at the fracture site while bone cells will die. The surrounding fibroblasts survive and start dividing. Platelets then release platelet-derived growth factors (PDGF) TGF- β causing local inflammation and swelling.¹⁵ Other secreted cytokines such as tumor necrosis factor-alpha (TNF- α), and interleukin-1, -6, -11 and -18 (IL-1, -6, -11 and -18) will lead to the recruitment of inflammatory cells which will in turn recruit MSCs at the site

A



B




Fig. 2 (A) A histological stained image of a growth plate.⁴ (B) The different stages of endochondral ossification as it occurs in long bones (adapted from Biology-OpenStax College, download for free at <http://cnx.org/contents/185cbf87-c72e-48f5-b51e-f14f21b5eabd@9.83>).⁵

of injury.¹⁶ Receptors TNFR1 and TNFR2 are activated with TNFR2 being specific to bone repair. This leads to the formation of a soft callus. The MSCs then divide and differentiate into osteogenic cells. Intra-membranous ossification takes place at the edge of the fracture where there is sufficient oxygen, whereas endochondral ossification occurs close to the fracture where the environment is hypoxic.¹⁷ A fibrocartilaginous callus forms to stabilize the bone injury. An external callus consisting of hyaline cartilage surrounds the fracture while an internal callus made of cartilage and collagen forms in the bone marrow cavity. Revascularization follows and phagocytic cells clean up the debris. The bony callus starts forming when new spongy bone trabeculae appear in the fibrocartilaginous callus. Mineralization of the matrix begins 3–4 weeks after the injury and extends up to 2–3 months, until union of the fracture occurs. However, in order for the bone to restore its biomechanical properties, the excess material needs to be removed through a remodelling process. The exterior of the bone and the interior of the medullary canal are resorbed by the osteoclasts for up to a year in some cases.¹⁵ And in the occurrence of an open fracture or bone excision due to a tumor,

it is very difficult for the bone to repair itself without any external aid. This results in impaired chondrogenesis due to insufficient blood supply and the inability to maintain mechanical stability. The development of an atrophic fibrous non-union or a cartilaginous callus with a hypertrophic non-union can be seen as the healing processes take place.¹⁷

Critical-sized defects

Although the bone is a self-healing tissue, in many cases when the bone loss exceeds the critical size, and the osteogenesis is compromised. This is due to many factors like the reduced expression of certain factors involved chondrocyte maturation and osteoblasts differentiation such as COX-2, BMP2 and various Wnts. Unsuccessful bone repair may also be due to impaired revascularization in gaps that are too large, thus not providing enough nutrients and oxygen.¹⁵ Currently, in the literature, the term “critical-sized defect” (CSD) generally refers to an animal model with an introduced bony defect that is most suitable for studying bone repair mechanisms.¹⁸ The bone defect must affect both cancellous and cortical bone, be stable and minimize fracture.¹⁹ The size of the induced defect




Fig. 3 Creation of the defect in a rodent. Removal of (A) skin and (B) periosteum. (C) A trephine is used to cut the calvarial bone resulting in a (D) scored calvarium (adapted from Spicer *et al.*, 2012).¹

in a rat must be between 6–8 mm.^{1,18} The defect is defined as “the smallest size intraosseous wound in a particular bone and species of animal that will not heal spontaneously during the lifetime of the animal”.²⁰ According to Cacchioli *et al.*, the CSD healing is usually evaluated by both the quantity and the quality of the newly regenerated bone; the best tissue quality being formed in a relatively short time.¹⁶ The evaluation of the newly formed bone relies on several imaging and immunocytochemistry techniques, such as microcomputed tomography, radiography, histology, and immunocytochemistry, among others.^{21–24}

Currently the rodent model is the most studied with its well-established calvarial, mandibular and long bone models (Fig. 3).¹ Rats make excellent models for CSD with 8 mm defects in the calvaria, 4 mm in the mandible and 12 mm in the long bones. Rabbit models have a 5–20 mm calvarial defect, 5 mm mandible defect and 6 mm long bone defect. Cats’ long bones do not heal at 1.5 times the diameter of the shaft. Dogs’ calvaria has a 20 mm gap, their mandibles have a 3 cm defect and their long bones have a defect 2 times the shaft diameter. Pigs were also used in some studies with femoral defects of 6–12 cm. Horses and guinea pigs were also used as CSD models but to a lesser extent. Among non-human primates, baboons were tested with a 15 mm calvarial defect and rhesus monkeys with a 4 cm mandible defect.²⁵ Numerous bone repair approaches are currently under study; however, they necessitate intensive investigation before they can be applied to clinical trials. Such an approach makes use of bio-material constructs, which are progressively gaining interest as state-of-the-art bone graft materials.

Ideal bone regeneration according to the “diamond concept”

Bone repair research currently focuses on five general therapeutic targets: osteogenesis, vascularization, growth factors, mechanical environment and osteoconductive scaffolds (Fig. 4). However, using each element on its own does not




Fig. 4 Diamond concept for the design of scaffolds in bone regeneration.

always yield consistent results. This calls for a more efficient approach that tackles numerous aspects of bone repair. The “diamond concept” established by Giannoudis *et al.*^{26,27} states that the five major elements for successful bone regeneration should ideally be studied in a combination of at least three. This strategy, termed “polytherapy”, usually focuses on investigating the osteogenic cells, the growth factors and the scaffolds, with the assumption that the mechanical environment is provided and that angiogenesis will ensue.²⁸ The cell types that have shown most osteogenic potential for implantation in bone defects are MSCs, embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), adipose derived stem cells (ADSCs) and exfoliated deciduous teeth stem cells (SHED). These cells, which can progress from progenitors to fully matured bone cells, are employed at different stages of bone repair.²⁹

The cellular models of choice to investigate cytocompatibility are usually MSCs, pre-osteoblasts (MC3T3), and fibroblasts (NIH3T3), among many others. This multifaceted approach can be applied to both animal and human bone defect models. Ideally, a bone substitute should have properties adapted to its specific clinical situation. Properties such as geometrical form, internal structure (pore size and distribution, crystallinity), surface topography, biocompatibility and resorbability are generally studied for scaffolds.³⁰ Adding growth factors and MSCs to the scaffolds can improve osteo-inductivity and osteoconductivity, respectively. For instance, bone morphogenetic proteins (BMPs) from the TGF- β super-family are already being used in clinical treatments for bone repair.³¹ Stem cells, whether directly transplanted or combined with scaffolds, have also shown potential for bone regeneration both *in vitro*^{32,33} and *in vivo*.³⁴ MSCs are the gold standard in bone repair as they have great osteogenic potency and are found in adult tissues.

Biomaterial scaffolds in bone regeneration

Three major classes of biomaterials are used to fabricate scaffolds: metals, ceramics and polymers.³⁵ Their different properties serve different purposes, such as biodegradability which is ideal in bone regenerating scaffolds but not as much in load-bearing devices.³⁶ Metals and alloys can be classified into three groups: titanium- and titanium alloy-based, stainless steels and cobalt-based alloys, all of which are biocompatible, relatively cheap in cost and possess good mechanical properties.³⁷ The second class of biomaterials, ceramics, regroups inorganic, non-metallic compounds, which also include carbon, bioglass and glass-ceramics. The two most common bioceramics used are hydroxyapatite and tricalcium phosphate. Another example of ceramic is pure coral which has been used as a preformed matrix with bone MSCs, loaded with BMP-2 and VEGF.³⁸ Upon implant, different interactions can occur with the surrounding tissue, giving rise to four types of ceramics: (i) bioinert which has minimal interaction with the body, (ii) bioactive which develops a specific biological response at the interface between the scaffold and fractured bone, (iii) porous which allows for cellular migration and infiltration, and (iv) resorbable which is biodegradable and eventually removed from the body.³⁹

Lastly, polymers are widely used in tissue engineering and are generally classified as natural or synthetic. Many of them have demonstrated good mechanical properties, biocompatibility and biodegradability that are generally required for tissue engineering applications.⁴⁰ Despite all these biomaterials being suitable in these applications, on their own, they can only mimic biological tissues to a certain extent, especially in the case of bone. For example, even though a ceramic can substitute the inorganic component of bone, it lacks the organic counterpart, for instance, collagen that creates the adequate microenvironment for osteogenesis to take place. This limitation makes way for the field of biocomposites.

As defined by Ramakrishna, a composite is a heterogeneous combination of two or more materials, which differ in morphology or composition on a micro- or nanoscale.³⁵ At least one material is the reinforcing phase which is embedded in another material, forming the matrix phase. Composite biomaterials can be grouped according to the shape of their reinforcing materials: (i) fibrous where fibers are incorporated in the matrix and (ii) particulate, whereby particles are introduced instead.⁴¹ The structure of a scaffold directly influences tissue formation by affecting cellular functions. The material as mentioned above is of crucial importance, but the geometry of the scaffold, its macro- and microstructures, as well as its physicochemical properties are also greatly considered during the selection and fabrication process. Porosity and interconnectivity between the pores are important for the distribution of nutrients, especially in a microenvironment that lacks neovascularisation. Additionally, the size of the pores determines the types of molecules that can navigate through or that can

Table 1 Biopolymers' young modulus

Biopolymer	Elastic modulus (kPa)	kPa of biopolymer-based composites
Chitosan	7.3×10^3 (ref. 45)	$40.5\text{--}1.33 \times 10^4$ (ref. 46 and 47)
Collagen	$2.9\text{--}9 \times 10^3$ (ref. 48)	$13.48\text{--}13.66 \times 10^6$ (ref. 49)
Gelatin	1–8 (ref. 50)	$10^2\text{--}1.1 \times 10^6$ (ref. 51 and 52)
Alginate	3.6–6.0 (ref. 53)	$8.4\text{--}4.3 \times 10^2$ (ref. 54 and 55)
Hyaluronan	1.5–2.7 (ref. 53)	2.07–10 (ref. 56 and 57)
Silk fibroin	$1.6\text{--}8 \times 10^3$ (ref. 58)	$4.7 \times 10^3\text{--}1.31 \times 10^4$

be entrapped for subsequent release. There is no consensus on the optimal porosity and pore size. Small pores (<200 μm) have shown proliferation and differentiation of osteoblasts limited to the periphery of the scaffold, whereas larger pores (>300 μm) have demonstrated bone regeneration throughout the entire scaffold. However, it was observed that the larger the pores the weaker the mechanical strength of the scaffold.²⁹ The surface-to-volume ratio is a characteristic that assesses the quantity of cells that can attach to the scaffold.⁴² Compression is another very important mechanical property that measures the effects of implantation on the scaffold. The measure for compression is the elastic or Young's modulus, which computes the necessary force to compress a material, otherwise known as the stiffness of the material.⁴³ Different biopolymers have different Young's moduli and the values cover a wider range for composites made of these biopolymers (Table 1). Degradation rate and resorption are assessed in scaffolds in order to find a controllable rate that will match the cell and tissue growth *in vitro* and *in vivo*.⁴⁴

Furthermore, cellular behavior is of the utmost importance when designing a scaffold. The cell–biomaterial interactions are related to the molecular exchanges that take place at the interface between the biomaterial and the surrounding cells. The elemental composition and release from the biomaterial, the van der Waals forces at work, the wettability of the surface, and topography come into play to influence cell adhesion and spreading, cell proliferation and differentiation, as well as protein adhesion and adsorption.^{42,59} Once more, where monolithic biomaterials may be lacking in stiffness, roughness or biological mimicry, the biocomposites can help to improve the regenerating performance at the cell–biomaterial interface.

Fabrication of scaffolds can be grouped by their various techniques. Textile methods, like electrospinning that make nonwoven fibers have been one of the earlier used to make scaffolds. Particulate-leaching is a technique that can control pore size and once the salts introduced they are leached away. Phase separation is another technique that creates porous scaffolds either by solid–liquid phase separation or by liquid–liquid phase separation. More recently, 3D printing a technology that deposits polymer powders in sequential layers has been reported. Self-assembly is another up-and-coming technique which requires no human intervention to form patterned scaffolds. For a more extensive review on the fabrication methods of scaffolds, please refer to Ma's articles.^{60,61}

Composites can incorporate two or more biomaterials from all three groups: metal, ceramics and polymers including both natural and synthetic ones, depending on the properties sought. When a composite is a mixture only consisting of two or more polymers, it is generally referred to as polymer blend. And while there are many reviews^{62–64} covering various biocomposites including synthetic polymer blends, little is reported on biocomposites made out of natural polymers as a matrix for bone substitute or scaffolding in the context of osteogenesis. In this article, we aim to provide direction with a comprehensive review of the state-of-the-art of using natural polymers in the fabrication of biocomposite for bone repair (Table 2).

Chitosan-based scaffolds

Chitosan is the deacetylated form of chitin, an abundant natural polymer found in the exoskeleton of crustaceans. It is recognized for its biodegradability and biocompatibility.⁶⁵ Chitosan and ceramics are often combined to compensate for the lack of strength of polymers and the brittleness of ceramics. Some recent examples include the fabrication of a 3D nanocomposite consisting of chitosan, gelatin and nano-silica. This scaffold was obtained by lyophilisation and compared with pure chitosan/gelatin for bone repair. The cellular response to scaffold was studied on an osteosarcoma cell line where the composite biomaterial presented superior qualities for cell attachment/proliferation and mineralization than either chitosan or chitosan/gelatin scaffolds, proving that composite biomaterials offer more than their monolithic compounds.⁶⁶ A similar scaffold was developed by freeze-drying a hydrogel made from α -chitin and nano-hydroxyapatite (nHA). Cell attachment and viability studies, as well as biomineralization assays, indicated that these scaffolds would be promising in bone repair applications (Fig. 5).⁶⁷ Gentile *et al.* investigated a chitosan/gelatin blend containing CEL2, a bioactive glass. The composite was cross-linked with genipin for enhanced mechanical strength.⁶⁸ Two cell lines were used to test cytocompatibility and proliferation, revealing that osteogenic properties of the scaffolds can be calibrated by controlling the pore size through bioglass content to obtain optimal performance for both soft and hard skeletal tissues. In other cases, composites are made by mixing synthetic and/or natural materials with chitosan, which helps to balance the properties of the polymers used. For example, a chitosan-alginate biocomposite with fucoidan was developed for bone repair applications, in which a MG-63 cell line was used for the *in vitro* studies. It was found that, when compared to the controls of chitosan and chitosan-alginate, the scaffold increased cellular proliferation as well as enhanced alkaline phosphatase secretion, a mineralization marker.⁶⁹ Porosity and water retention were also superior in the composite scaffolds, which is an indication of adequate cell adhesion and infiltration as well as good protein adsorption efficiency. Lastly, chitosan and chitosan-based biocomposites are also employed as coatings on

metallic implants. For instance, chitosan, alginate-cross-linked chitosan and pectin-cross-linked chitosan were used to coat Ti-6Al-4V surfaces and were tested for cytocompatibility using osteoblasts.⁷⁰ The titanium–aluminum alloy was found to have higher proliferative properties after coating, especially with cross-linked chitosan.

Collagen-based scaffolds

Collagen is the most abundant protein in the animal kingdom. It is a highly insoluble fibre that makes up the extracellular matrix and connective tissues.⁷¹ Kamakura *et al.* recently studied the implantation of an octacalcium phosphate (OCP)/collagen sponge in a rat cranial bone defect over a period of 4–12 weeks. A newly formed bone was observed and very few granules from the implants remained, indicating good osteogenesis and resorbability.²² A very similar study using OCP/collagen scaffolds also demonstrated the osteoconductive effects of a polymer–ceramic composite.²³ Scaffolds made of shelled silica nanospheres electrosprayed into a 3D foam were implanted in rats for 2 weeks, which showed a favourable tissue response. The constructs were composed of polylactic acid (PLA) and polyethylene glycol (PEG) nanospheres combined with collagen and loaded with acidic FGF.²⁴ Simpler forms of calcium phosphate are also used in combination with polymers to create efficient biocomposite scaffolds. nHA is recognized for its great biocompatibility and osteoconductivity, for which it is often used pre-clinically and clinically for treating bone defects. Xia *et al.* fabricated a biomimetic collagen–apatite (Col–Ap) by a controllable freeze-casting method.⁷² The Col–Ap suspensions were prepared by first extracting collagen from rat tails and then freeze-drying it. The collagen was then dissolved under acidic conditions and mixed with simulated body fluid in order to get mineralization (apatite crystals). The Col–Ap solutions were freeze dried and then cross-linked before a subsequent freeze-drying step. It yielded a 3D scaffold that was subsequently tested in mice calvaria bone defects. After 4 weeks, the results showed dynamic new bone formation throughout the entire defect area (Fig. 6). Among the mixed polymer composites, a biomineralized collagen/alginate/silica scaffold was fabricated by Lee *et al.* and the cellular activities were assessed with pre-osteoblasts.⁷³

The results showed that cell proliferation and osteogenic gene expression levels were higher on the composite scaffold *versus* the chitosan and chitosan/alginate controls. As for the collagen–metal composites being tested *in vivo*, there is a biphasic type I collagen/glycosaminoglycans/porous titanium (CGT) composite.⁷⁴ Titanium powder was mixed with hydrogen peroxide, methylcellulose and PEG to form a slurry. The slurry went through a foaming and drying process to give porous titanium shaped cylinders. Type I collagen was mixed with glycosaminoglycans to make a slurry that was subsequently poured over the titanium cylinders and freeze-dried. Those were implanted in a beagle with osteochondral defects,

Table 2 Summary of biopolymers in bone regeneration

Biopolymers	Properties	Materials added	<i>In vitro</i>	<i>In vivo</i>	Clinical trials
Chitosan (CH)	<ul style="list-style-type: none"> • Deacetylated form of chitin • Biocompatible • Biodegradable • Cellular-binding • Wound-healing • Anti-bacterial • Anti-fungal • Fibrous protein 	<ul style="list-style-type: none"> • GE/silicon dioxide⁶⁶ • nHA⁶⁷ • Bioactive glass⁶⁸ • AL/fucoidan⁶⁹ • CS coated Ti-6Al-4V⁷⁰ • GE/rhBMP2¹¹⁶ • Octacalcium phosphate^{22,23} 	<ul style="list-style-type: none"> • Human osteosarcoma (MG63)⁶⁶ • MG63, Vero, NIH3T3, and nHDF cells⁶⁷ • MG63, human periosteal-derived precursor cells (PCs)⁶⁸ • MG63⁶⁹ • Mouse osteoblast 7F2⁷⁰ • hMSCs¹¹⁶ • MC3T3-E1²⁴ • MC3T3-E1⁷³ • MSCs⁷⁴ • MC3T3-E1¹⁰³ 	<ul style="list-style-type: none"> • Male KM mice (leg)¹¹⁶ • Male Wistar rats (crania)²² • Male Wistar rats (calvaria)²³ • Male Sprague-Dawley rats²⁴ • Transgenic mice carrying the pOBCol3.6GFP transgene (calvaria)⁷² • Male beagle (femur)⁷⁴ • Sheep (tibia)⁹⁹ • Male New Zealand White rabbits (condyle)¹⁰¹ • Male Wistar rats (femur)¹⁰³ 	<ul style="list-style-type: none"> • 21 patients (mandibular non-union)¹¹⁹ • 32 patients (periodontal defect)¹¹⁰
Collagen (CO)	<ul style="list-style-type: none"> • Most abundant protein in the body • Biocompatible • Biodegradable • Highly elastic 	<ul style="list-style-type: none"> • PLA/PEG/silica nanospheres loaded with aFGFs²⁴ • Apatite⁷² • AL/silica⁷³ • Glycosaminoglycan/porous titanium¹¹⁷ • Non-crystalline HA/ASC/PRP⁹⁹ • Calcium sulfate hemihydrate/nHA/loaded with rhBMP2¹¹⁸ • HA/loaded with bisphosphonates and BMPs¹⁰³ • Teicoplanin¹¹⁹ • Deproteinized cancellous bone particles¹¹⁰ • Bioactive glass⁷⁶ • Porous HA⁷⁵ • PEG/PPG⁷⁷ • PVA/BCP⁷⁸ • Hyaluronan/AL⁷⁹ • PCL/HA¹⁰² • PPF/VEGF/BMP2^{107,108} • β-TCP⁸⁰ • Octacalcium phosphate⁸¹ • Fibrin⁸² • GE/agarose w/calcium salt of polyphosphate⁸³ • Strontium⁸⁴ • Ce(III)⁸⁵ • TiO₂/simvastatin¹⁰⁰ • Heparin/BMP2¹⁰⁹ • nHA⁸⁶ • nHA/HY-dopamine conjugate⁸⁷ • Tetracycline⁸⁸ • Nano calcium phosphate⁸⁹ • PCL⁹⁰ • CS/nHA⁹¹ 	<ul style="list-style-type: none"> • hMSCs⁷⁵ • Human osteoblasts⁷⁷ • MG63⁷⁸ • hBM-MSCs, MC3T3⁷⁹ • MSCs¹⁰² • Human osteoblasts (CRL-11372)⁸⁰ • Mouse bone marrow stromal cells (ST-2)⁸¹ • hBM-MSCs⁸² • Human osteosarcoma cells (SaOS-2)⁸³ • BM-MSCs⁸⁴ • MG63⁸⁵ • Primary human osteoblasts (hOBs)¹⁰⁰ • C2C12¹⁰⁹ • MC3T3⁸⁷ • Human gingiva-derived MSCs⁸⁸ • Rabbit BM-MSCs⁸⁹ • hMSCs⁹⁰ • hMSCs⁹¹ 	<ul style="list-style-type: none"> • Male Sprague-Dawley rats (crania)⁷⁸ • Mice⁷⁹ • Male Sprague-Dawley rats (crania)¹⁰² • Male Fischer-344 rats (crania)¹⁰⁷ • Male Fischer-344 rats (crania)¹⁰⁸ • ICR mice (calvaria)⁸¹ • Male Sprague-Dawley rats (spine)¹⁰⁹ • Male New Zealand white rabbits (back and knee)⁸⁹ • Male New Zealand white rabbits (calvaria)⁹⁰ • Female nude mice⁹¹ 	
Gelatin (GE)	<ul style="list-style-type: none"> • Denatured collagen • Thermoreversible gelation • Biocompatible • Biodegradable 				
Alginate (AL)	<ul style="list-style-type: none"> • Water-soluble copolymers • Extracted from brown seaweed • Biocompatible • Biodegradable 				
Silk fibroin (SF)	<ul style="list-style-type: none"> • Linear structure with β-sheet structure • Biocompatible • Physical and mechanical properties • Easy processability 				

Table 2 (Contd.)

Biopolymers	Properties	Materials added	<i>In vitro</i>	<i>In vivo</i>	Clinical trials
Hyaluronan (HY)	<ul style="list-style-type: none"> • Nonsulfated glycosaminoglycan • Abundant in the extracellular matrix • Biocompatible • Biodegradable • Physico-chemical properties 	<ul style="list-style-type: none"> • Sodium alginate/nano-bioactive glass⁹² • Poly(dimethylsiloxane)⁹³ • CS/CO-1¹²⁰ • Poly(vinyl phosphonic acid)⁹⁴ • Inorganic polyphosphate⁹⁵ • Calcium phosphate NP⁹⁶ • GE/BCP⁹⁷ 	<ul style="list-style-type: none"> • MG63⁹² • MC3T3⁹³ • hMSCs¹²⁰ • HepG2⁹⁴ • MC3T3-E1⁹⁵ • BMSCs⁹⁷ 	<ul style="list-style-type: none"> • Male Wistar rats (femur)⁹⁶ • New Zealand white rabbit (femur) 	




Fig. 5 (A) Representation of composite scaffolds: (i) α -chitin control, (ii) α -chitin + 0.5% nHA composite scaffold and (iii) α -chitin + 1% nHA composite scaffold. (B) (i–iii) Are scanning electron microscopy (SEM) images of cell attachment of α -chitin control, α -chitin + 0.5% nHA and α -chitin + 1% nHA scaffolds respectively at 12 h and (iv–vi) are SEM images of cell attachment of α -chitin control, α -chitin + 0.5% nHA and α -chitin + 1% nHA scaffolds respectively at 72 h (adapted from Kumar *et al.*, 2011).⁶⁷

and abundant subchondral bone formation was observed 3 months after the surgery.

Gelatin-based scaffolds

Gelatin is a natural protein with low toxicity that is derived by denaturing collagen. It is ubiquitously used as a gelling agent. In bone tissue repair, a study showed that a porous gelatin-covered HA scaffold had a 163% increase in proliferation when cultured with human MSCs (hMSCs).⁷⁵ A gelatin-bioactive glass composite scaffold was recently developed by Lacroix *et al.* and its controlled porosity shows promising potential for bone formation after incubation in simulated body fluid (SBF). After 5 days of immersion into SBF, the formation of calcium phosphate was visible on both the surface of the bioglass particles and the gelatin walls.⁷⁶ Another study has shown that a poly(ethylene glycol)–poly(propyleneglycol)–poly(ethylene glycol) (PEG–PPG–PEG)/pregelatinized starch composite can be used as a bone wax substitute; cytotoxic assays have revealed that it is harmless to osteoblasts.⁷⁷ Linh *et al.* developed fiber mats composed of polyvinyl alcohol (PVA)/gelatin (GE) loaded with various amounts of biphasic calcium phosphate (BCP)




Fig. 6 Green Fluorescent Protein (GFP) images showing bone formation at the cross-section of the calvarial defect implanted with Col-Ap loaded with mCOB cells (A) 10x scanning image with cyan + TRITC + tpz + DF channel. (B) 10x scanning image with cyan + TRITC + tpz + DAPI – 4 weeks. Scale bar: 500 μ m (adapted from Xia *et al.*, 2013).⁷²




Fig. 7 (A) SEM image shows the open pore architecture and smooth pore walls of the GHA matrix. (B) Micro-CT image shows the presence of interconnected pores which enhances cell recruitment (adapted from Singh *et al.*, 2014).⁷⁹

nanoparticles.⁷⁸ Studies in rats showed an increase in bone formation with the 50% PVA/GE-50% BCP blend, indicating its potential use in bone regeneration. Singh *et al.* presented a 3D gelatin/hyaluronan/alginate (GHA) blend that was freeze-dried and then cross-linked with calcium chloride (CaCl_2) (Fig. 7). The implantation of this scaffold in mice demonstrated pronounced osseointegration, recruitment of cells and reduced inflammatory response compared to controls.⁷⁹

Alginate-based scaffolds

Alginate is an anionic linear co-polymer derived from marine seaweed. Like chitosan, it is often used as a biomaterial due to

its biocompatibility and biodegradability. Beta-tricalcium phosphate (β -TCP)/alginate scaffolds were recently fabricated *via* 3D printing and presented promising *in vitro* results toward bone regeneration applications.⁸⁰ A mouse calvarial CSD was used to investigate the bone repair capacities of an OCP/alginate scaffold over a period of three weeks. Results showed that the sporadic bone formation around the defect was dependent on the pore size of the scaffold.⁸¹ Furthermore, a fibrin and alginate hydrogel appeared to support bone marrow derived MSCs (BM-MSCs) chondrogenesis *in vitro*.⁸²

Very recently, another hydrogel made of a sodium alginate matrix stabilized with gelatin was tested with human osteoblast-like SaOS-2 cells and was shown to increase cellular mineralization on the surface of the matrix (Fig. 8).⁸³ Lastly, Tu *et al.* recently studied the biocompatibility of an injectable alginate-strontium hydrogel with BM-MSCs as a precursor for bone tissue repair.⁸⁴ Morais *et al.* developed several alginate-based hydrogels with cerium ions, which showed improved MG63 cell activity compared with the control with no Ce(III) ions.⁸⁵

Silk-based scaffolds

Silk fibroin (SF) is a linear polypeptide with a β -sheet conformation. It is commonly used in tissue engineering due to its low immunogenicity. It was recently shown that biomineralization could be regulated by the nano-sized features in SF proteins. This occurred due to the repulsive forces resulting from the double layering of SF. With increasing SF concentration, these forces gradually changed the nano-HA morphology. This allowed the SF to function as a template for biomineraliza-




Fig. 8 SEM images show the mineral deposits on SaOS-2 cell surfaces. (A–C) Mineral deposits, nodules (no), formed onto cells, (D–F) nodules (no) formed onto SaOS-2 cells that had been encapsulated into alginate/gelatin hydrogel (adapted from Neufurth *et al.*, 2014).⁸³




Fig. 9 Cell attachment analysis. (A–C) Negative control groups were observed by SEM (no cells, PBS) at day 1. (D–F) GMSCs attached to the TC-SFMs (0, 1, 5, and 10%) were observed by SEM at day 1. Scale bar in the figures indicates 10 μm (adapted from Jin *et al.*, 2014).⁸⁸

tion.⁸⁶ Kim *et al.* prepared a SF hydrogel with nHA nanoparticles on its surface, and when tested on MC-3T3 cells, the surface-modified hydrogel was shown to have significantly higher proliferation abilities than the pure SF hydrogel group.⁸⁷ A similar study done with gingiva-derived MSCs (GMSCs) demonstrated excellent cell adhesion and proliferative potential with tetracycline-loaded silk fibroin membranes (TC-SFMs) (Fig. 9).⁸⁸ Yan *et al.* recently tested a bilayered silk/silk-nano calcium phosphate scaffold in a rabbit knee CSD model. Firm osseointegration and bone growth was observed in the host tissue.⁸⁹ A SF/polycaprolactone (PCL) composite was implanted in a calvarial rabbit CSD. Quantitative analysis showed that the composite scaffold generated a larger amount of newly formed bone than both the empty control group and the PCL scaffold group.⁹⁰ A new composite developed by Lai *et al.* demonstrated excellent osteogenic properties both *in vitro* and *in vivo*. The SF/CS/nHA scaffold in which the nHA was embedded by preelectrospinning *in situ* promoted proliferation and osteogenic differentiation, as well as ectopic bone formation in nude mice.⁹¹

Hyaluronan-based scaffolds

Hyaluronan (HY) is a linear polysaccharide with repetitive D-glucuronic acid and N-acetyl-D-glucosamine monosaccharide. The adjustable structure and texture of HY makes it a great candidate for bone tissue engineering applications. Sohrabi *et al.* tested an injectable visco-elastic paste composed of HY/sodium alginate/nano-bioactive glasses on osteoblastic cells. The release of Ca and Si ions, from the bioactive glasses, into the culture media enhanced the alkaline phosphatase activity of the cells.⁹² Micro-patterning of a HY hydrogel on poly(dimethylsiloxane) (PDMS) was found to enhance adhesion and induce proliferation of MC-3T3, as well as showing excellent biocompatibility.⁹³ A biomineralized hydrogel comprised of HY cross-linked with vinyl phosphonic acid was created to mimic the extracellular matrix for improved bone repair. It was




Fig. 10 (A) Histology of covalently (HA, HABP, HA + CP) and non-covalently (HABPCP) cross-linked formulations after 4 weeks of implantation in bone tissue. (B) Bone regeneration after 4 weeks of implantation; error bars indicate the standard deviation (adapted from Nejadnik *et al.*, 2014).⁹⁶

tested on human hepatoma HepG2 cells for viability and did not show any adverse effects.⁹⁴

The enhancement of osteogenic differentiation was also observed in an investigation by Wu *et al.* The group conjugated inorganic polyphosphate chains onto HY macromers to make a bioactive hydrogel. When incubated with MC-3T3, osteoconductivity was much higher in the HY/polyphosphate group than the control stimulated with free polyphosphates.⁹⁵ An injectable nanocomposite scaffold consisting of bisphosphonated (BP) HY and calcium phosphate (CP) nanoparticles was developed by Nejadnik *et al.* for the repair of rat bone defects. The performance after 1 and 4 weeks was evaluated and it was found that the non-covalent interactions of the bisphosphonate groups and the CP nanoparticles allowed for better cellular infiltration and degradation of the scaffold. Abundant bone formation was observed throughout the material in the bone defect (Fig. 10).⁹⁶ A HY/GE hydrogel was loaded through a dropwise method into a spongy porous BCP matrix. Implantation of the HY/GE/BCP scaffold in rabbit femurs demonstrated rapid bone formation and collagen mineralization, as well as the positive staining of bone-forming proteins: osteopontin, osteocalcin and collagen type I.⁹⁷

Composite scaffolds as delivery systems

Scaffolds that act as a delivery system are extremely useful. Not only do they provide a mechanical structure for the new tissue to grow on, they can also enhance bone repair by releasing drugs or growth factors locally. Among the biomolecules used to augment bone-cell response, there is TGF- β , BMP, insulin-like growth factors (IGF), PDGF, and fibroblast growth factors (FGF),³ as well as bisphosphonates and antiresorptive drugs such as Denosumab.⁹⁸ Biocomposites offer many advantages as delivery scaffolds. For instance, their different materials degrade at different rates, allowing for a controlled release of

molecules. Also, the hydrophobic and hydrophilic interactions between the biocomposite and delivery factor can be manipulated for improved molecule entrapment.

The delivery modes can be divided into three categories: (i) molecules released by seeded cells; (ii) molecules entrapped in the scaffold or attached to the surface, and (iii) molecules encapsulated in micro- or nanoparticles within the scaffold. Platelet-rich plasma (PRP), a source of growth factors, has also been integrated into some scaffolds to accelerate bone growth. PRP was used in combination with adipose tissue derived stem cells (ASCs) or BM-MSCs on mineralized collagen sponges.⁹⁹ The nHA-coated construct was introduced in a sheep tibia CSD model for 26 weeks. The results showed that the BM-MSCs had the greatest osteogenic potential when paired with PRP. Even though the results did not show a significant difference, there was a trend for larger amount of bone formation for the PRP-group. Many molecules are now being directly integrated into the scaffold during synthesis or attached on the surface. For instance, an alginate-coated TiO₂ hydrogel containing simvastatin (SIM) was tested *in vitro* for bone regeneration.¹⁰⁰ SIM, known for enhancing bone formation, was mixed in the alginate solution prior to coating. The release was found to be sustained for a period of 15–17 days and to induce osteoblast differentiation. The cumulative release indicated that the drug remained entrapped in the scaffold even after 19 days of incubation.

Another injectable composite was made of nHA/collagen and calcium sulfate hemihydrate, subsequently loaded with rhBMP-2.¹⁰¹ The loaded scaffold was implanted in a rabbit femoral condyle defect and as suspected, was proven to be more bioactive than the scaffold alone. Lee *et al.* functionalized the interface of an electrospun gelatin/PCL scaffold by attaching proteins (fusion of fibronectin and osteocalcin (FN-OCN)) *via* a nHA coating.¹⁰² *In vivo* testing in a rat calvarial defect model showed a higher amount of new bone formation in the FN-OCN-functionalized biocomposite compared to the control. Another study evaluated the efficacy of a porous composite collagen–nHA scaffold for delivering recombinant BMPs and bisphosphonates.¹⁰³ The molecules were loaded into the scaffold after a 24-hour incubation at 37 °C following its synthesis. The results showed that a composite construct was ideal for dual delivery systems. Similarly, Quinlan *et al.* developed a collagen–HA scaffold that delivered rhBMP-2 *via* PLGA and alginate microparticles. The construct with the PLGA microparticles showed higher pro-osteogenic effect compared to the alginate microparticles; this was demonstrated both *in vitro* and *in vivo* (after 8 weeks of implantation in calvarial defects in rats).¹⁰⁴ More recently, Ronca *et al.* tested a PLLA/PCL/hyaluronan derivative functionalized with BMP-7.¹⁰⁵ The 3D tube-shaped scaffold was made *via* a combination of phase inversion/salt leaching and filament-winding technology. The entrapment and sustained release of the protein were successful and led to positive outcomes in the *in vivo* testing. The composite was found to be osteoinductive due to the scaffold and osteoconductive due to the BMP-7 release.

In another study, a gel scaffold made from cellulose and heparin showed osteogenesis *via* the targeted delivery of BMP-7 *in vitro*.¹⁰⁶

To increase the efficacy of a delivery system, researchers opt for encapsulating molecules in particles. This ensures a controlled release profile that can be altered by modifying the particles' properties. A dual delivery system of BMP-2 and vascular endothelial growth factor (VEGF) encapsulated in gelatin microparticles and embedded in a porous poly(propylene fumarate) (PPF) scaffold was studied by Patel *et al.*¹⁰⁷ and Young *et al.*¹⁰⁸ The dual release achieved full bone union in two-thirds of the CSD rats as opposed to only a third of the rats in the control groups which were only implanted with the unloaded PPF scaffold. The effectiveness of alginate microbeads in a poly-epsilon caprolactone TCP scaffold (mPCL-TCP) was investigated by Abbah *et al.*¹⁰⁹ The microbeads, containing heparin and BMP-2, were loaded into the pores right before implantation into rats. Compared to a collagen scaffold, the composite dual delivery system demonstrated increased *de novo* bone formation. The above reported studies support the efficacy of composite biomaterials over monolithic biomaterials as drug delivery systems.

Composite biomaterials in clinical trials

There are currently clinical trials that use commercially available osteoconductive composite biomaterials as bone substitutes. For instance a study on periodontal defects used a composite bovine-derived xenograft with a collagen membrane (BDX Coll + GTR) to treat deep intra-bony defects.¹¹⁰ The scaffold is formulated by embedding deprotonized cancellous bone particles in the collagen matrix. The results of 32 patients were evaluated one year after the treatment, and they demonstrated a much higher, significant improvement over the control group, which was treated with access flap surgery. In an early clinical trial on patients with post-operative tumor lesions, a composite calcium sulfate/calcium phosphate injectable scaffold was used to improve bone repair as shown by the gradual resorption of the scaffold and new bone growth in 27 out of the 29 patients included in the trial.¹¹¹ In 11 out of 13 patients, the application of a composite biomaterial containing calcium sulphate and HA for the treatment of osteolytic bone tumours was also reported to consolidate bone formation with great integration of the graft material into the host bone.¹¹² More recently, studies have shown that combining scaffolds with growth factors help improve periodontal infrabony defects. An example is a biphasic HA/ β -TCP composite with an enamel matrix derivative¹¹³ which clearly demonstrated that the composite materials in combination with biological molecules perform better than a monolithic unblended material. TricOs, macroporous biphasic ceramic phosphate granules, was recently used in association with fibrin to fill the bony defects of seven patients' tibia. However, the results were still at a preliminary stage and the healing processes were analysed by X-ray, showing some new bone formation.¹¹⁴

Summary and perspectives

To date, the review of the literature evidently demonstrates that composite biomaterials significantly improve bone regeneration. Incorporating metals and ceramics into readily available polymers appears to be the new trend to follow for scaffolds mimicking the skeletal microenvironment (Table 1). Hence, composite biomaterials could be used to provide both strength and improved biological properties, such as cellular adhesion. Various material combinations show potential applications as bone substitutes. However, two shortcomings were revealed through the study of the current literature: (i) the lack of adequate *in vivo* data and clinical trials and (ii) the limited testing of different material blends.

There are presently numerous *in vitro* assays that assess the cellular behaviour of scaffolds. Even though these preliminary studies are necessary, they are unfortunately not sufficient to evaluate the compatibility and efficiency of scaffolds in the body. Animal studies will however demonstrate how different the requirements for the composite scaffold are from that of *in vitro* studies. For example, mechanical loads on the scaffold cannot be determined *via* cellular assays, nor can the immune system reaction. And with the lack of *in vitro* studies comes the scarcity of clinical trials; the few that were reported above sum up the most recent studies. To counter the second limitation, more combinations of biomaterials need to be tested.

This will allow the finding of appropriate scaffolds for different models of bone defects. An area that is particularly unexplored is the combination of polymers, ceramics and biological elements. Polymers can provide the right amount of elasticity; ceramics can provide the structural backbone, while growth factors can accelerate the regeneration processes. It is highly recommended that future studies focus on different combinations of bone graft substitutes as was also suggested by Schindler *et al.*¹¹² Other parameters that can also be optimised for clinical applications are the mode of admission of the scaffold, such as injectability, the integration of a delivery system and the rate of gelling of a hydrogel.¹¹⁵ The present review demonstrates the significance of combining different materials with the aim of accelerating bone regeneration following a bone defect, notably reinforcing natural polymers. Among the various blends that can be made, natural polymer/ceramics composites seem to be the most prevalent. The efficacy of these scaffolds can be improved by entrapping growth factors and cytokines inside. Recent findings involving the entrapment of drugs inside composite scaffolds have shown increased and faster bone formation; this area of biomaterials should without a doubt be investigated thoroughly.

Acknowledgements

The authors acknowledge the CIHR and NSERC contribution through CIHR-POP, CHRP, NSERC-Discovery grants. K. Jahan expresses her gratitude to the Faculty of Dentistry for salary support through the Excellence Award, as well as Dr Mina

Mekhail and Dr Laila Benameur for their guidance and Dr Amir Foudeh and Dr Feriel Melaine for their assistance with Lightroom, Inkscape and ChemBioUltra.

Notes and references

- 1 P. P. Spicer, J. D. Kretlow, S. Young, J. A. Jansen, F. K. Kasper and A. G. Mikos, *Nat. Protoc.*, 2012, 7, 1918–1929.
- 2 G. M. Calori, E. Mazza, M. Colombo and C. Ripamonti, *Injury*, 2011, 42(Supplement 2), S56–S63.
- 3 M. Ulrich and W. Hans Peter, *Bone and Cartilage Engineering*, Springer, Berlin, Heidelberg, 2006, ch. 3, pp. 47–63.
- 4 L. C. U. a. Junqueira, J. Carneiro and A. N. Contopoulos, in *A Concise medical library for practitioner and student, Lange Medical Publications, Appleton & Lange*, Lange Medical Books/McGraw Hill, McGraw Hill, Los Altos, Calif., Norwalk, Conn., New York, 13th edn, 2013.
- 5 A. Yael, C. Jung, D. Jean, J. Vladimir, W. Robert and R. Connie, *OpenStax College, Biology*, OpenStax CNX, 2013.
- 6 U. Meyer and H. P. Wiesmann, in *Bone and Cartilage Engineering*, Springer, Berlin, Heidelberg, 2006, ch. 2, pp. 7–46.
- 7 T. Yang, M. Grover, K. S. Joeng and B. Lee, in *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, John Wiley & Sons, Inc., 2013, pp. 119–126.
- 8 C. Colnot and T. Alliston, in *Bone and Development*, ed. F. Bronner, M. C. Farach-Carson and H. I. Roach, Springer, London, 2010, vol. 6, ch. 2, pp. 25–37.
- 9 U. Meyer and H. P. Wiesmann, in *Bone and Cartilage Engineering*, Springer, Berlin, Heidelberg, 2006, ch. 4, pp. 65–72.
- 10 E. M. Bueno and J. Glowacki, *Synth. Lect. Tissue Eng.*, 2011, 3, 1–220.
- 11 D. J. J. de Gorter and P. ten Dijke, in *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, John Wiley & Sons, Inc., 2013, pp. 15–24.
- 12 Q. Wang and E. Seeman, in *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, John Wiley & Sons, Inc., 2013, pp. 127–134.
- 13 C. Qian, W. Lei, W. Zhengke, S. Xiaojuan, L. Junming and Y. Xu, *Current Topics in Bone Biology*, World Scientific Publishing Co., River Edge, NJ, USA, 2005.
- 14 H. C. Anderson and I. Shapiro, in *Bone and Development*, ed. F. Bronner, M. C. Farach-Carson and H. I. Roach, Springer, London, 2010, vol. 6, ch. 3, pp. 39–64.
- 15 M. J. Zuscik, in *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, John Wiley & Sons, Inc., 2013, pp. 90–98.
- 16 C. Antonio, S. Brunella, R. Francesca, M. Filippo Maria, B. Paolo and G. Carlo, *Ann. Fac. Med. Vet.-Univ. Parma*, 2006, 26, 97–110.
- 17 R. Marsell and T. A. Einhorn, *Injury*, 2011, 42, 551–555.
- 18 I. Drosse, E. Volkmer, S. Seitz, H. Seitz, R. Penzkofer, K. Zahn, U. Matis, W. Mutschler, P. Augat and M. Schieker, *Tissue Eng., Part C*, 2008, 14, 79–88.

- 19 C. Bosch, B. Melsen and K. Vargervik, *J. Craniofac. Surg.*, 1998, **9**, 310–316.
- 20 J. P. Schmitz and J. O. Hollinger, *Clin. Orthop. Relat. Res.*, 1986, 299–308.
- 21 P. Niemeyer, K. Fechner, S. Milz, W. Richter, N. P. Suedkamp, A. T. Mehlhorn, S. Pearce and P. Kasten, *Biomaterials*, 2010, **31**, 3572–3579.
- 22 S. Kamakura, K. Sasaki, T. Homma, Y. Honda, T. Anada, S. Echigo and O. Suzuki, *J. Biomed. Mater. Res., Part A*, 2007, **83**, 725–733.
- 23 T. Kawai, T. Anada, Y. Honda, S. Kamakura, K. Matsui, A. Matsui, K. Sasaki, S. Morimoto, S. Echigo and O. Suzuki, *Tissue Eng., Part A*, 2009, **15**, 23–32.
- 24 T. H. Kim, M. Eltohamy, M. Kim, R. A. Perez, J. H. Kim, Y. R. Yun, J. H. Jang, E. J. Lee, J. C. Knowles and H. W. Kim, *Acta Biomater.*, 2014, **10**, 2612–2621.
- 25 J. O. Hollinger and J. C. Kleinschmidt, *J. Craniofac. Surg.*, 1990, **1**, 60–68.
- 26 P. V. Giannoudis, T. A. Einhorn and D. Marsh, *Injury*, 2007, **38**(Suppl 4), S3–S6.
- 27 P. V. Giannoudis, T. A. Einhorn, G. Schmidmaier and D. Marsh, *Injury*, 2008, **39**(Suppl 2), S5–S8.
- 28 G. M. Calori and P. V. Giannoudis, *Injury*, 2011, **42**, 1191–1193.
- 29 A. R. Amini, C. T. Laurencin and S. P. Nukavarapu, *Crit. Rev. Biomed. Eng.*, 2012, **40**, 363–408.
- 30 P. Janicki and G. Schmidmaier, *Injury*, 2011, **42**(Supplement 2), S77–S81.
- 31 G. Pelled, A. Ben-Arav, C. Hock, D. G. Reynolds, C. Yazici, Y. Zilberman, Z. Gazit, H. Awad, D. Gazit and E. M. Schwarz, *Tissue Eng., Part B*, 2010, **16**, 13–20.
- 32 Y. H. Liao, Y. H. Chang, L. Y. Sung, K. C. Li, C. L. Yeh, T. C. Yen, S. M. Hwang, K. J. Lin and Y. C. Hu, *Biomaterials*, 2014, **35**, 4901–4910.
- 33 W. TheinHan, J. Liu, M. Tang, W. Chen, L. Cheng and H. H. Xu, *Bone Res.*, 2013, **4**, 371–384.
- 34 H. Ding, Y. S. Gao, Y. Wang, C. Hu, Y. Sun and C. Zhang, *Stem Cells Dev.*, 2014, **23**, 990–1000.
- 35 M. R. Seeram Ramakrishna, T. S. Sampath Kumar and W. O. Soboyejo, in *Biomaterials*, CRC Press, 2010, pp. 1–33.
- 36 L. Horstink, H. T. Faber, M. J. F. de Wolf, C. A. J. Dun, C. W. R. J. Cremers and M. K. S. Hol, *Otol. Neurotol.*, 2012, **33**, 1013–1017, DOI: 10.1097/MAO.1010b1013e318259b318236c.
- 37 M. R. Seeram Ramakrishna, T. S. Sampath Kumar and W. O. Soboyejo, in *Biomaterials*, CRC Press, 2010, pp. 161–186.
- 38 C. Xiao, H. Zhou, G. Liu, P. Zhang, Y. Fu, P. Gu, H. Hou, T. Tang and X. Fan, *Biomed. Mater.*, 2011, **6**, 015013.
- 39 M. R. Seeram Ramakrishna, T. S. Sampath Kumar and W. O. Soboyejo, in *Biomaterials*, CRC Press, 2010, pp. 187–215.
- 40 M. R. Seeram Ramakrishna, T. S. Sampath Kumar and W. O. Soboyejo, in *Biomaterials*, CRC Press, 2010, pp. 217–262.
- 41 M. R. Seeram Ramakrishna, T. S. Sampath Kumar and W. O. Soboyejo, in *Biomaterials*, CRC Press, 2010, pp. 263–298.
- 42 U. Meyer and H. P. Wiesmann, *Bone and cartilage engineering*, Springer, Berlin, New York, 2006.
- 43 J. R. Woodard, A. J. Hilldore, S. K. Lan, C. J. Park, A. W. Morgan, J. A. Eurell, S. G. Clark, M. B. Wheeler, R. D. Jamison and A. J. Wagoner Johnson, *Biomaterials*, 2007, **28**, 45–54.
- 44 D. W. Hutmacher, *Biomaterials*, 2000, **21**, 2529–2543.
- 45 T. Nishino, R. Matsui and K. Nakamae, *J. Polym. Sci., Part B: Polym. Phys.*, 1999, **37**, 1191–1196.
- 46 H. L. Kim, G. Y. Jung, J. H. Yoon, J. S. Han, Y. J. Park, D. G. Kim, M. Zhang and D. J. Kim, *Mater. Sci. Eng., C*, 2015, **54**, 20–25.
- 47 J. Zhang, A. Deng, A. Zhou, Y. Yang, L. Gao, Z. Zhong and S. Yang, *J. Biomater. Sci., Polym. Ed.*, 2015, **26**, 585–599.
- 48 N. Sasaki and S. Odajima, *J. Biomech.*, 1996, **29**, 655–658.
- 49 S. Ramalingam, A. Al-Rasheed, A. ArRejaie, N. Nooh, M. Al-Kindi and K. Al-Hezaimi, *Odontology*, 2015, 1–12.
- 50 C. Amador, M. W. Urban, S. Chen, Q. Chen, K.-N. An and J. F. Greenleaf, *IEEE Trans. Biomed. Eng.*, 2011, **58**, 1706–1714.
- 51 K. Siimon, H. Siimon and M. Jarvekulg, *J. Mater. Sci.: Mater. Med.*, 2015, **26**, 5375.
- 52 A. Sharma, S. Bhat, V. Nayak and A. Kumar, *Mater. Sci. Eng., C*, 2015, **47**, 298–312.
- 53 C. D. Markert, X. Guo, A. Skardal, Z. Wang, S. Bharadwaj, Y. Zhang, K. Bonin and M. Guthold, *J. Mech. Behav. Biomed. Mater.*, 2013, **27**, 115–127.
- 54 M. S. Kim and G. Kim, *Carbohydr. Polym.*, 2014, **114**, 213–221.
- 55 H. S. Kim, M. Song, E. J. Lee and U. S. Shin, *Mater. Sci. Eng., C*, 2015, **51**, 139–147.
- 56 H. J. Lee, A. Sen, S. Bae, J. S. Lee and K. Webb, *Acta Biomater.*, 2015, **14**, 43–52.
- 57 S. C. Choi, M. A. Yoo, S. Y. Lee, H. J. Lee, D. H. Son, J. Jung, I. Noh and C. W. Kim, *J. Biomed. Mater. Res., Part A*, 2015, **103**, 3072–3080.
- 58 C. Jiang, X. Wang, R. Gunawidjaja, Y.-H. Lin, M. K. Gupta, D. L. Kaplan, R. R. Naik and V. V. Tsukruk, Mechanical properties of robust ultrathin silk fibroin films, DTIC Document, 2007.
- 59 S. G. Piperni, E. R. Takamori, S. Sartoretto, K. B. Paiva, J. M. Granjeiro, R. C. de Oliveira and W. F. Zambuzzi, *Arch. Biochem. Biophys.*, 2014, **561**, 88–98.
- 60 P. X. Ma, *Mater. Today*, 2004, **7**, 30–40.
- 61 P. X. Ma, *Adv. Drug Delivery Rev.*, 2008, **60**, 184–198.
- 62 G. H. Billström, A. W. Blom, S. Larsson and A. D. Beswick, *Injury*, 2013, **44**(Supplement 1), S28–S33.
- 63 D. Ozdil and H. M. Aydin, *J. Chem. Technol. Biotechnol.*, 2014, **89**, 1793–1810.
- 64 T. Garg and A. K. Goyal, *Expert Opin. Drug Deliv.*, 2014, **11**, 767–789.

- 65 M. Fan, Q. Hu and K. Shen, *Carbohydr. Polym.*, 2009, **78**, 66–71.
- 66 K. C. Kavya, R. Jayakumar, S. Nair and K. P. Chennazhi, *Int. J. Biol. Macromol.*, 2013, **59**, 255–263.
- 67 P. T. S. Kumar, S. Srinivasan, V.-K. Lakshmanan, H. Tamura, S. V. Nair and R. Jayakumar, *Int. J. Biol. Macromol.*, 2011, **49**, 20–31.
- 68 P. Gentile, M. Mattioli-Belmonte, V. Chiono, C. Ferretti, F. Baino, C. Tonda-Turo, C. Vitale-Brovarone, I. Pashkuleva, R. L. Reis and G. Ciardelli, *J. Biomed. Mater. Res., Part A*, 2012, **100**, 2654–2667.
- 69 J. Venkatesan, I. Bhatnagar and S. K. Kim, *Mar. Drugs*, 2014, **12**, 300–316.
- 70 H.-Y. Lin and J.-H. Chen, *Carbohydr. Polym.*, 2013, **97**, 618–626.
- 71 H. F. Lodish, *Molecular cell biology*, W.H. Freeman and Co., New York, 2013.
- 72 Z. Xia, X. Yu, X. Jiang, H. D. Brody, D. W. Rowe and M. Wei, *Acta Biomater.*, 2013, **9**, 7308–7319.
- 73 H. Lee, Y. Kim, S. Kim and G. Kim, *J. Mater. Chem. B*, 2014, **2**, 5785–5798.
- 74 X. Duan, X. Zhu, X. Dong, J. Yang, F. Huang, S. Cen, F. Leung, H. Fan and Z. Xiang, *Mater. Sci. Eng., C*, 2013, **33**, 3951–3957.
- 75 A. Tampieri, G. Celotti, E. Landi, M. Montecchi, N. Roveri, A. Bigi, S. Panzavolta and M. C. Sidoti, *J. Mater. Sci.: Mater. Med.*, 2003, **14**, 623–627.
- 76 J. Lacroix, E. Jallot and J. Lao, *Chem. Eng. J.*, 2014, **256**, 9–13.
- 77 J. Suwanprateeb, W. Suvannaprak, F. Thammarakcharoen, W. Chokevivat and P. Rukskul, *J. Mater. Sci.: Mater. Med.*, 2013, **24**, 2881–2888.
- 78 N. T. Linh, K. H. Lee and B. T. Lee, *J. Biomed. Mater. Res., Part A*, 2013, **101**, 2412–2423.
- 79 D. Singh, A. Tripathi, S. Zo, D. Singh and S. S. Han, *Colloids Surf., B*, 2014, **116**, 502–509.
- 80 G. S. Diogo, V. M. Gaspar, I. R. Serra, R. Fradique and I. J. Correia, *Biofabrication*, 2014, **6**, 025001.
- 81 T. Fuji, T. Anada, Y. Honda, Y. Shiwaku, H. Koike, S. Kamakura, K. Sasaki and O. Suzuki, *Tissue Eng., Part A*, 2009, **15**, 3525–3535.
- 82 K. Ma, A. L. Titan, M. Stafford, C. Zheng and M. E. Levenston, *Acta Biomater.*, 2012, **8**, 3754–3764.
- 83 M. Neufurth, X. Wang, H. C. Schroder, Q. Feng, B. Diehl-Seifert, T. Ziebart, R. Steffen, S. Wang and W. E. Muller, *Biomaterials*, 2014, **35**, 8810–8819.
- 84 Y. Tu, T. Wu, A. Ye, J. Xu, F. Guo and X. Cheng, *Chin. J. Repar. Reconstr. Surg.*, 2013, **27**, 1499–1505.
- 85 D. S. Morais, M. A. Rodrigues, M. A. Lopes, M. J. Coelho, A. C. Mauricio, R. Gomes, I. Amorim, M. P. Ferraz, J. D. Santos and C. M. Botelho, *J. Mater. Sci.: Mater. Med.*, 2013, **24**, 2145–2155.
- 86 X. Huang Xiaowei, X. Liu, S. Liu, A. Zhang and Q. Lu, *J. Biomed. Mater. Res., Part B*, 2014, **102**, 1720–1729.
- 87 H. H. Kim, J. B. Park, M. J. Kang and Y. H. Park, *Int. J. Biol. Macromol.*, 2014, **70**, 516–522.
- 88 S.-H. Jin, H. Kweon, J.-B. Park and C.-H. Kim, *J. Surg. Res.*, 2014, **192**, e1–e9.
- 89 L.-P. Yan, J. Silva-Correia, M. B. Oliveira, C. Vilela, H. Pereira, R. A. Sousa, J. F. Mano, A. L. Oliveira, J. M. Oliveira and R. L. Reis, *Acta Biomater.*, 2015, **12**, 227–241.
- 90 S. Kim Beom, K. E. Park, M. H. Kim, H. K. You and J. Lee, *Int. J. Nanomed.*, 2015, **10**, 485–502.
- 91 G.-J. Lai, K. T. Shalumon and J.-P. Chen, *Int. J. Nanomed.*, 2015, **10**, 567–584.
- 92 M. Sohrabi Mehri, S. Hesarakhi and A. Kazemzadeh, *J. Biomed. Mater. Res., Part B*, 2014, **102**, 561–573.
- 93 S. Park Hyo, S. Y. Lee, H. Yoon and I. Noh, *Pure Appl. Chem.*, 2014, **86**, 1911–1922.
- 94 Y. Kim So and J.-S. Park, *J. Appl. Polym. Sci.*, 2014, **131**.
- 95 T. H. Wu Andy, T. Aoki, M. Sakoda, S. Ohta and S. Ichimura, *Biomacromolecules*, 2015, **16**, 166–173.
- 96 M. R. M. R. Nejadnik, X. Yang, M. Bongio, H. S. Alghamdi and J. J. J. P. Van den Beucken, *Biomaterials*, 2014, **35**, 6918–6929.
- 97 T. B. Nguyen Thuy Ba Linh and B.-T. Lee, *Tissue Eng., Part A*, 2014, **20**, 1993–2004.
- 98 M. L. Brandi, *Expert Opin. Investig. Drugs*, 2012, **21**, 1169–1176.
- 99 P. Niemeyer, K. Fechner, S. Milz, W. Richter, N. P. Suedkamp, A. T. Mehlhorn, S. Pearce and P. Kasten, *Biomaterials*, 2010, **31**, 3572–3579.
- 100 H. Pullisaar, H. Tiainen, M. A. Landin, S. P. Lyngstadaas, H. J. Haugen, J. E. Reseland and E. Ostrup, *J. Tissue Eng.*, 2013, **4**, 2041731413515670.
- 101 J. Liu, K. Mao, Z. Liu, X. Wang, F. Cui, W. Guo and S. Yang, *PLoS One*, 2013, **8**, e75668.
- 102 J. H. Lee, J. H. Park, A. El-Fiqi, J. H. Kim, Y. R. Yun, J. H. Jang, C. M. Han, E. J. Lee and H. W. Kim, *Acta Biomater.*, 2014, **10**, 2750–2761.
- 103 C. M. Murphy, A. Schindeler, J. P. Gleeson, N. Y. Yu, L. C. Cantrill, K. Mikulec, L. Peacock, F. J. O'Brien and D. G. Little, *Acta Biomater.*, 2014, **10**, 2250–2258.
- 104 E. Quinlan, A. Lopez-Noriega, E. Thompson, H. M. Kelly, S. A. Cryan and F. J. O'Brien, *J. Controlled Release*, 2015, **198**, 71–79.
- 105 A. Ronca, V. Guarino, M. G. Raucci, F. Salamanna, L. Martini, S. Zeppetelli, M. Fini, E. Kon, G. Filardo, M. Marcacci and L. Ambrosio, *J. Biomater. Appl.*, 2014, **29**, 715–727.
- 106 M. Fan, J. Yan, H. Tan, D. Ben, Q. He, Z. Huang and X. Hu, *Macromol. Biosci.*, 2014, **14**, 1521–1527.
- 107 Z. S. Patel, S. Young, Y. Tabata, J. A. Jansen, M. E. K. Wong and A. G. Mikos, *Bone*, 2008, **43**, 931–940.
- 108 S. Young, Z. S. Patel, J. D. Kretlow, M. B. Murphy, P. M. Mountziaris, L. S. Baggett, H. Ueda, Y. Tabata, J. A. Jansen, M. Wong and A. G. Mikos, *Tissue Eng., Part A*, 2009, **15**, 2347–2362.
- 109 S. A. Abbah, J. Liu, J. C. Goh and H. K. Wong, *Tissue Eng., Part A*, 2013, **19**, 350–359.

- 110 A. Sculean, G. C. Chiantella, P. Windisch, N. B. Arweiler, M. Brex and I. Gera, *J. Clin. Periodontol.*, 2005, **32**, 720–724.
- 111 R. K. Heck Jr., *Treatment of Benign Bone Lesions with a Calcium Sulfate/Calcium Phosphate Composite: Early Clinical Experience*, Wright Medical Technology, Inc., Memphis, TN, 2008.
- 112 O. S. Schindler, S. R. Cannon, T. W. Briggs and G. W. Blunn, *J. Orthop. Surg.*, 2008, **16**, 66–74.
- 113 D. De Leonardis and M. Paolantonio, *J. Periodontol.*, 2013, **84**, 444–455.
- 114 M. Durand, D. Chauveaux, M. Moinard, T. Fabre, J. L. Rouvillain, M. Bagot d'Arc and G. Daculsi, *TricOs™ and Fibrin Sealant Combined for Bone Defect Filling: from Pre-Clinical Tests to Prospective Clinical Study, Preliminary Human Data*, 2008.
- 115 M. Mekhail, J. Daoud, G. Almazan and M. Tabrizian, *Adv. Healthcare Mater.*, 2013, **2**, 1126–1130.
- 116 L. Cao, J. A. Werkmeister, J. Wang, V. Glattauer, K. M. McLean and C. Liu, *Biomaterials*, 2014, **35**, 2730–2742.
- 117 X. Duan, X. Zhu, X. Dong, J. Yang, F. Huang, S. Cen, F. Leung, H. Fan and Z. Xiang, *Mater. Sci. Eng., C*, 2013, **33**, 3951–3957.
- 118 J. Liu, K. Mao, Z. Liu, X. Wang, F. Cui, W. Guo, K. Mao and S. Yang, *PLoS One*, 2013, **8**, e75668.
- 119 S. Rupprecht, L. Petrovic, B. Burchhardt, J. Wiltfang, F. W. Neukam and K. A. Schlegel, *J. Biomed. Mater. Res., Part B*, 2007, **83**, 314–319.
- 120 S. Mathews Smitha, R. Bhonde, P. K. Gupta and S. Totey, *J. Biomed. Mater. Res., Part B*, 2014, **102**, 1825–1834.